Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
  • Sign in
    My account
    Logout
AI 90-DAY FORECAST
BULLISH SIGNAL DETECTED
██.█% Sign up free to reveal

Lenz Therapeutics, Inc. (LENZ) AI Forecast

Our AI detected a significant signal for Lenz Therapeutics, Inc.. Create a free account to see the exact price target.

✓ Free account • ✓ 30-day free trial

$LENZ Bullish Signal Full forecast available
Sign Up Free

Lenz Therapeutics, Inc. (LENZ) Stock Forecast 2025

Lenz Therapeutics, Inc. (LENZ) AI Stock Price Forecast & Investment Analysis

Lenz Therapeutics, Inc. Stock Price Chart and Technical Analysis

Loading chart...

Lenz Therapeutics, Inc. (LENZ) - Comprehensive Stock Analysis & Investment Research

Deep dive into Lenz Therapeutics, Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on April 2, 2026, 7:25 a.m. (UTC)

Lenz Therapeutics, Inc. Investment Summary

When evaluating whether Lenz Therapeutics, Inc. (LENZ) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Lenz Therapeutics, Inc. (LENZ) operates within the Life Sciences sector, specifically in the Biological Products, (No Diagnostic Substances) industry. The company employs approximately 119 people. With a market capitalization of $293 million, the company is a small-cap stock that may offer higher growth potential but also carries higher volatility.

Financial Performance Analysis

Our comprehensive financial analysis covers Lenz Therapeutics, Inc.'s revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Lenz Therapeutics, Inc. along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Lenz Therapeutics, Inc. is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Lenz Therapeutics, Inc.

Sign Up Free
Corporate Identity

Lenz Therapeutics, Inc. (Stock Symbol: LENZ) is a prominent company operating within the Life Sciences sector, with a specific focus on the Biological Products, (No Diagnostic Substances) industry. The company's shares are publicly traded on the Nasdaq exchange.

Leadership & Workforce

Detailed information about Lenz Therapeutics, Inc.'s leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Lenz Therapeutics, Inc....

Sector & Industry Analysis

In-depth sector dynamics and industry context for Lenz Therapeutics, Inc....

Unlock Full Company Profile

Get complete details about Lenz Therapeutics, Inc.

Sign Up Free
Revenue & Growth Analysis

Lenz Therapeutics, Inc. generates annual revenues of $25 million , representing an emerging company in its growth phase.

Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Lenz Therapeutics, Inc....

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Lenz Therapeutics, Inc....

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Lenz Therapeutics, Inc....

Unlock Financial Analysis

Get complete financial metrics for Lenz Therapeutics, Inc.

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Lenz Therapeutics, Inc.'s AI Price Forecast

Join 10,000+ investors using our 67%+ accurate AI predictions

4,000+ Stocks Analyzed
67%+ Accuracy Rate
Daily Updates
Start 30-Day Free Trial →

✓ 30-day free trial • ✓ Cancel anytime

Strategic Market Position

Lenz Therapeutics, Inc. strategically competes in the highly dynamic Biological Products, (No Diagnostic Substances) marketplace. As a small-cap company, it represents an emerging market participant with potentially significant growth opportunities. Small-caps often offer greater growth potential as they capture market share and scale their operations, though this comes with higher risk and volatility. Success at this stage can lead to substantial returns for early investors who identify winning business models.

Industry Competitive Landscape

Lenz Therapeutics, Inc. competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency
Financial Strength & Leverage

Lenz Therapeutics, Inc. (LENZ) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Lenz Therapeutics, Inc. stock analysis.

Deep dive into Lenz Therapeutics, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Lenz Therapeutics, Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Lenz Therapeutics, Inc.: With a P/E ratio of -6.72, the market sees the stock as potentially undervalued.

P/E Ratio -6.72x
P/B Ratio 1.03x
Market Cap $293M
EPS $-1.63
Book Value/Share $9.07
Revenue/Share $0.81
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Lenz Therapeutics, Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Lenz Therapeutics, Inc.:

Understanding Financial Health Metrics

What these metrics mean: These ratios assess Lenz Therapeutics, Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Lenz Therapeutics, Inc.:

Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Lenz Therapeutics, Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Lenz Therapeutics, Inc.:

Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Lenz Therapeutics, Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Lenz Therapeutics, Inc.:

Understanding Financial Statement Data

What these metrics mean: Key figures from Lenz Therapeutics, Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Lenz Therapeutics, Inc.: With annual revenue of $25M, Lenz Therapeutics, Inc. represents a smaller but potentially high-growth operation.

Income Statement
Total Revenue $25M
Operating Income -$107M
Net Income -$148M
R&D Expense $72M
Balance Sheet Highlights (% Of Assets)
Dividend & Shareholder Information
Shares Outstanding 31M
Growth Metrics (YoY)
EPS Growth -18.7%

Latest Lenz Therapeutics, Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Lenz Therapeutics, Inc. (LENZ) stock price and investment outlook.

More news available

Sign up free to read all 9 news articles and stay updated on market developments.

Sign Up Free to Read More

Lenz Therapeutics, Inc. Competitors & Peer Analysis - Life Sciences Sector

Comparative analysis of Lenz Therapeutics, Inc. against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
Acumen Pharmaceuticals, Inc. ABOS ██% $188M -1.9x 2.7x
Abpro Holdings, Inc. ABP ██% $310K x 0.0x
Abpro Holdings, Inc. ABPO ██% $460K x x
Arcellx, Inc. ACLX ██% $6.65B -74.1x 16.5x
Alpha Cognition Inc. ACOG ██% $135M x 2.2x
Adaptimmune Therapeutics Plc ADAP ██% $77M -13.2x -11.8x
Adma Biologics, Inc. ADMA ██% $2.17B 14.8x 4.6x
Adaptive Biotechnologies Corp ADPT ██% $2.23B -4.6x 10.2x
Adverum Biotechnologies, Inc. ADVM ██% $95M -1.8x 2.2x
Agenus Inc AGEN ██% $120M 1047.3x 33.5x
Agentix Corp. AGTX ██% $2M x 249.3x
Aim Immunotech Inc. AIM ██% $2M -0.5x 0.9x
Aim Immunotech Inc. AIMI ██% $1M x x
Alector, Inc. ALEC ██% $284M -1.2x 9.3x
Aligos Therapeutics, Inc. ALGS ██% $49M -19.2x 0.9x
Allogene Therapeutics, Inc. ALLO ██% $593M -1.4x 2.0x
Alvotech ALVO ██% $1.13B x x
Amgen Inc AMGN ██% $190.18B 24.7x 22.0x
Apogee Therapeutics, Inc. APGE ██% $5.77B -20.5x 4.3x
Aptose Biosciences Inc. APTOF ██% $4M x x
Argenx Se ARGX ██% $46.03B x x
Armata Pharmaceuticals, Inc. ARMP ██% $378M -1.0x 16.4x
Artiva Biotherapeutics, Inc. ARTV ██% $165M x 1.5x
Leonabio, Inc. ATHA ██% $23M -0.2x 0.9x
Atara Biotherapeutics, Inc. ATRA ██% $42M 1.3x 4.7x
Atyr Pharma Inc ATYR ██% $84M -3.6x 1.2x
Aura Biosciences, Inc. AURA ██% $427M -4.9x 3.1x
Autolus Therapeutics Plc AUTL ██% $365M x 2.1x
Anavex Life Sciences Corp. AVXL ██% $289M -17.3x 2.3x
Bioatla, Inc. BCAB ██% $11M -1.1x 23.3x
Biocardia, Inc. BCDA ██% $12M -0.6x 13.9x
Brainstorm Cell Therapeutics Inc. BCLI ██% $10M -4.9x 6.0x
Biocryst Pharmaceuticals Inc BCRX ██% $2.35B 8.9x 70.5x
Black Diamond Therapeutics, Inc. BDTX ██% $133M 6.0x 1.2x
Beam Therapeutics Inc. BEAM ██% $2.46B -12.6x 2.0x
Biogen Inc. BIIB ██% $26.98B 20.9x 1.5x
Biontech Se BNTX ██% $22.47B x x
Cabaletta Bio, Inc. CABA ██% $269M -1.6x 2.4x
Candel Therapeutics, Inc. CADL ██% $365M -4.6x 7.0x
C4 Therapeutics, Inc. CCCC ██% $262M -2.6x 1.0x
Cidara Therapeutics, Inc. CDTX ██% $6.49B -1.0x 15.4x
Creative Medical Technology Holdings, Inc. CELZ ██% $7M -3.4x 1.0x
Cero Therapeutics Holdings, Inc. CERO ██% $650K x -196.2x
Cullinan Therapeutics, Inc. CGEM ██% $840M -4.1x 2.1x
Compugen Ltd CGEN ██% $208M 2.9x 2.0x
Cg Oncology, Inc. CGON ██% $5.39B x 7.2x
Cognition Therapeutics Inc CGTX ██% $79M -0.5x 2.3x
Coherus Oncology, Inc. CHRS ██% $261M 1.6x 4.3x
Calidi Biotherapeutics, Inc. CLDI ██% $2M -0.9x 0.6x
Cellectis S.A. CLLS ██% $340M x x
Compass Therapeutics, Inc. CMPX ██% $968M -4.8x 4.9x
Mosaic Immunoengineering Inc. CPMV ██% $5M x 20.9x
Caribou Biosciences, Inc. CRBU ██% $142M -1.5x 1.0x
Cardiff Oncology, Inc. CRDF ██% $110M -4.0x 2.4x
Cardiol Therapeutics Inc. CRDL ██% $156M x x
Curis Inc CRIS ██% $21M -0.3x 3.9x
Crispr Therapeutics Ag CRSP ██% $4.68B -12.1x 2.4x
Champions Oncology, Inc. CSBR ██% $82M 32.9x 19.2x
Cel Sci Corp CVM ██% $29M -0.9x 2.6x
Dbv Technologies S.A. DBVT ██% $1.14B -3.3x 6.8x
Dbv Technologies S.A. DBVTF ██% $10K x 0.0x
Ginkgo Bioworks Holdings, Inc. DNA ██% $395M -13.9x 0.8x
Denali Therapeutics Inc. DNLI ██% $3.07B -8.7x 3.0x
Precision Biosciences Inc DTIL ██% $137M -2.2x 1.5x
Dyadic International Inc DYAI ██% $31M -7.3x 25.0x
Editas Medicine, Inc. EDIT ██% $255M -0.8x 9.4x
Elutia Inc. ELUT ██% $45M 0.9x 1.6x
Engene Holdings Inc. ENGN ██% $453M 3.7x 1.6x
Entera Bio Ltd. ENTX ██% $53M 8.5x 4.0x
Viskase Holdings, Inc. ENZN ██% $4M x 10.3x
Estrella Immunopharma, Inc. ESLA ██% $45M -3.1x 289.4x
Evaxion A/S EVAX ██% $33M x x
Exelixis, Inc. EXEL ██% $11.56B 14.8x 5.4x
Exozymes Inc. EXOZ ██% $71M x 20.9x
Fate Therapeutics Inc FATE ██% $143M -1.3x 0.7x
4d Molecular Therapeutics, Inc. FDMT ██% $504M -3.0x 1.0x
Fennec Pharmaceuticals Inc. FENC ██% $219M 1758.3x 6.2x
Finch Therapeutics Group, Inc. FNCH ██% $15M 0.5x 1.1x
Futuretech Ii Acquisition Corp. FTII ██% $52M x -0.7x
Futuretech Ii Acquisition Corp. FTIIU ██% $14M x -0.8x
Gilead Sciences, Inc. GILD ██% $174.11B 20.5x 7.7x
Monte Rosa Therapeutics, Inc. GLUE ██% $1.37B 59.5x 5.9x
Genenta Science S.P.A. GNTA ██% $16M x 1.3x
Green Planet Bio Engineering Co. Ltd. GPLB ██% $340K x x
Greenland Mines Ltd GRML ██% $45M x 4.5x
Halozyme Therapeutics, Inc. HALO ██% $7.70B 24.3x 157.8x
Humacyte, Inc. HUMA ██% $131M -3.3x 42.3x
Immunitybio, Inc. IBRX ██% $7.22B -3.6x 57.4x
Inhibikase Therapeutics, Inc. IKT ██% $239M -1.0x 1.4x
Imagenebio, Inc. IMA ██% $56M x 0.4x
Immunocore Holdings Plc IMCR ██% $1.54B x 4.0x
Immatics N.V. IMTX ██% $1.34B x x
Immunovant, Inc. IMVT ██% $5.10B -14.5x 5.2x
In8bio, Inc. INAB ██% $14M x 0.5x
Inhibrx Biosciences, Inc. INBX ██% $873M -6.8x 109.2x
Mink Therapeutics, Inc. INKT ██% $45M -1.5x 6.7x
Inmune Bio, Inc. INMB ██% $33M -2.5x 1.4x
Intensity Therapeutics, Inc. INTS ██% $14M -2.2x 1.2x
Iovance Biotherapeutics, Inc. IOVA ██% $1.42B -4.5x 2.0x
Century Therapeutics, Inc. IPSC ██% $394M -0.7x 2.5x
Invivyd, Inc. IVVD ██% $375M -0.4x 1.6x
Jasper Therapeutics, Inc. JSPR ██% $22M -3.2x 5.4x
Kalaris Therapeutics, Inc. KLRS ██% $136M x 1.7x
Klotho Neurosciences, Inc. KLTO ██% $56M x 5.7x
Kodiak Sciences Inc. KOD ██% $2.64B -2.5x 16.8x
Krystal Biotech, Inc. KRYS ██% $7.56B 36.9x 6.2x
Kymera Therapeutics, Inc. KYMR ██% $6.91B -17.8x 4.4x
Kyverna Therapeutics, Inc. KYTX ██% $530M x 2.3x
Ladrx Corp LADX ██% $20K x 0.1x
Lineage Cell Therapeutics, Inc. LCTX ██% $387M -4.7x 8.7x
Lenz Therapeutics, Inc. LENZ ██% $293M -6.7x 1.0x
Liminatus Pharma, Inc. LIMN ██% $7M x x
Leonabio, Inc. LONA ██% $94M x 3.4x
Lexeo Therapeutics, Inc. LXEO ██% $414M -0.4x 1.7x
Maze Therapeutics, Inc. MAZE ██% $1.43B x 4.0x
Mesoblast Ltd MESO ██% $2.07B x x
Meiragtx Holdings Plc MGTX ██% $737M -3.4x 201.5x
Metagenomi Therapeutics, Inc. MGX ██% $50M x 0.3x
Molecular Partners Ag MOLN ██% $162M x x
Moderna, Inc. MRNA ██% $19.71B -3.2x 2.3x
Neurocrine Biosciences Inc NBIX ██% $13.27B 27.7x 4.1x
Nkgen Biotech, Inc. NKGN ██% $2M -0.1x -0.2x
Neumora Therapeutics, Inc. NMRA ██% $399M -3.9x 3.0x
Novavax Inc NVAX ██% $1.51B 3.4x 40.0x
Ocugen, Inc. OCGN ██% $547M -4.3x 154.7x
Outlook Therapeutics, Inc. OTLK ██% $22M -0.2x 2.1x
Palisade Bio, Inc. PALI ██% $291M -0.2x 2.3x
Passage Bio, Inc. PASG ██% $22M -0.6x 1.2x
Vaxcyte, Inc. PCVX ██% $7.62B -20.4x 2.8x
Biomx Inc. PHGE ██% $8M 1.5x 0.8x
Pluri Inc. PLUR ██% $34M -1.4x 352.9x
Protalix Biotherapeutics, Inc. PLX ██% $173M 41.2x 3.6x
Pharmacyte Biotech, Inc. PMCB ██% $8M 0.3x 0.2x
Prime Medicine, Inc. PRME ██% $617M -1.5x 5.1x
Prokidney Corp. PROK ██% $526M x 0.0x
Qiagen N.V. QGEN ██% $9.11B x 2.6x
Quince Therapeutics, Inc. QNCX ██% $5M -1.7x 5.1x
Qrons Inc. QRON ██% $150K x x
Replimune Group, Inc. REPL ██% $602M -3.8x 2.9x
Repligen Corp RGEN ██% $6.61B 135.2x 3.1x
Regenxbio Inc. RGNX ██% $418M -1.8x 4.1x
Relay Therapeutics, Inc. RLAY ██% $1.84B -2.0x 3.2x
Revolution Medicines, Inc. RVMD ██% $19.08B -11.1x 11.7x
Recursion Pharmaceuticals, Inc. RXRX ██% $1.58B -4.7x 1.4x
Sab Biotherapeutics, Inc. SABS ██% $273M 20.6x 1.8x
Sana Biotechnology, Inc. SANA ██% $740M -2.1x 4.6x
Scilex Holding Co SCLX ██% $47M -0.4x 4.5x
Scinai Immunotherapeutics Ltd. SCNI ██% $2M -287.8x 0.3x
Sangamo Therapeutics, Inc SGMO ██% $82M -1.6x 13.1x
Solid Biosciences Inc. SLDB ██% $715M -0.9x 4.0x
Silexion Therapeutics Corp SLXN ██% $4M x 1.5x
Senti Biosciences, Inc. SNTI ██% $24M -1.1x 4.3x
Scholar Rock Holding Corp SRRK ██% $5.22B -18.5x 21.3x
Surrozen, Inc./De SRZN ██% $343M -0.5x 7.3x
Sutro Biopharma, Inc. STRO ██% $356M -1.0x 8.0x
Protara Therapeutics, Inc. TARA ██% $278M -2.1x 1.4x
Tarsus Pharmaceuticals, Inc. TARS ██% $2.87B -12.4x 8.4x
Tc Biopharm (Holdings) Plc TCBPY ██% $10K x 0.0x
Tscan Therapeutics, Inc. TCRX ██% $57M -4.6x 0.5x
Bio-Techne Corp TECH ██% $8.20B 101.1x 4.1x
Tectonic Therapeutic, Inc. TECX ██% $587M -8.9x 2.3x
Instil Bio, Inc. TIL ██% $56M -1.1x 0.5x
Tenaya Therapeutics, Inc. TNYA ██% $159M -2.5x 1.3x
Tourmaline Bio, Inc. TRML ██% $1.23B -3.5x 4.8x
Taysha Gene Therapies, Inc. TSHA ██% $1.26B -3.0x 5.1x
Titan Pharmaceuticals Inc TTNP ██% $6M -0.5x 2.2x
Tevogen Bio Holdings Inc. TVGN ██% $17M x 1274.2x
Twist Bioscience Corp TWST ██% $2.85B -12.6x 6.3x
Voyager Acquisition Corp./Cayman Islands VACH ██% $372M 41.3x 0.0x
Voyager Acquisition Corp./Cayman Islands VACHU ██% $68M 6.7x 0.0x
Valneva Se VALN ██% $548M x x
Vericel Corp VCEL ██% $1.61B 97.7x 4.6x
Vir Biotechnology, Inc. VIR ██% $1.47B -2.0x 1.8x
Vivosim Labs, Inc. VIVS ██% $4M x 1.0x
Vor Biopharma Inc. VOR ██% $738M -0.6x 11.2x
Vaxart, Inc. VXRT ██% $146M 8.9x 1.7x
Voyager Therapeutics, Inc. VYGR ██% $238M 570.6x 1.2x
Windtree Therapeutics Inc /De/ WINT ██% $320K -0.4x 0.1x
X4 Pharmaceuticals, Inc XFOR ██% $375M 6.4x 2.0x
Zeo Scientifix, Inc. ZEOX ██% $17M x 25.0x
Zivo Bioscience, Inc. ZIVO ██% $26M -31.3x 17.0x
Zura Bio Ltd ZURA ██% $565M x 5.6x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Lenz Therapeutics, Inc. Stock Forecast

How accurate are Lenz Therapeutics, Inc. stock predictions?

Our AI model shows a 31% Spearman correlation coefficient for LENZ predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Lenz Therapeutics, Inc. stock price forecasts?

Our analysis considers Lenz Therapeutics, Inc.'s financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Lenz Therapeutics, Inc. a good investment in 2025?

Based on our AI analysis, Lenz Therapeutics, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Lenz Therapeutics, Inc. forecasts updated?

Lenz Therapeutics, Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want a simpler view of Lenz Therapeutics, Inc.?

View simplified analysis on AI Stock Finder →

My Portfolio

Investment Dashboard

Loading your portfolio...